NO Synthase

Nitric oxide synthases; NOS

Nitric oxide synthases (NOSs) are a family of enzymes catalyzing the production of nitric oxide (NO) from L-arginine. NO synthases catalyze the oxidation of L-arginine to NO and L-citrulline. Mammals contain three NOS isoforms: neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS). NO produced from these different NOS isoforms is involved in a wide range of physiologic functions in the nervous, immune, and cardiovascular systems. Unregulated NO production can lead to pathologic conditions such as stroke, inflammation, and hypertension. Therefore, the control of NOS activity by isoform selective NOS inhibitors has great potential for therapeutic treatments of NO-related diseases.

NO Synthase Inhibitors, Agonists & Activators

1400W Dihydrochloride

Cat. No.: HY-18731

1400W dihydrochloride is a potent and selective inhibitor of human inducible **NO synthase** with K_i values of 7 nM.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

2-Iminobiotin

(Guanidinobiotin)

Cat. No.: HY-118700

2-Iminobiotin (Guanidinobiotin) is a biotin (vitamin H or B7) analog. 2-Iminobiotin is a reversible **nitric oxide synthases** inhibitor with K_is of 21.8 and 37.5μM for murine **iNOS** and rat **n-cNOS**, respectively.



Purity: >98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg

2-Iminobiotin hydrobromide

(Guanidinobiotin hydrobromide)

Cat. No.: HY-118700A

2-Iminobiotin hydrobromide (Guanidinobiotin hydrobromide) is a biotin (vitamin H or B7) analog. 2-Iminobiotin hydrobromide is a reversible **nitric oxide synthases** inhibitor with K_is of 21.8 and 37.5 μM for murine **iNOS** and rat **n-cNOS**, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

20-HETE

(20-hydroxy Arachidonic Acid)

Cat. No.: HY-15598

20-HETE (20-hydroxy Arachidonic Acid) is a CYP450 metabolite and a potent vasoconstrictor. 20-HETE is an endogenous inhibitor of the large-conductance **Ca^{2+}-activated K^+ channel** in renal arterioles.

Purity: >95.0%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

3',4'-Dihydroxyflavonol

(DiOHF)

Cat. No.: HY-111804

3',4'-Dihydroxyflavonol (DiOHF) is an effective antioxidant, which reduces superoxide and improves nitric oxide (**NO**) function in diabetic rat mesenteric arteries.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3-Bromo-7-nitroindazole

Cat. No.: HY-101175

3-Bromo-7-nitroindazole is a more potent and selective inhibitor of **neuronal nitric oxide synthase (nNOS)** than eNOS or inducible nitric oxide synthase (iNOS). 3-Bromo-7-nitroindazole affects the intercellular messenger nitric oxide (NO) synthesis throughout the body and brain.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

6-Biopterin

(L-Biopterin)

Cat. No.: HY-102015

6-Biopterin (L-Biopterin), a pterin derivative, is a **NO synthase** cofactor.

Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

7,8-Dihydroneopterin

Cat. No.: HY-136341

7,8-Dihydroneopterin, an inflammation marker, induces cellular **apoptosis** in astrocytes and neurons via enhancement of nitric oxide synthase (**iNOS**) expression. 7,8-Dihydroneopterin can be used in the research of neurodegenerative diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Agmatine sulfate

Cat. No.: HY-101238

Agmatine sulfate exerts modulatory action at multiple molecular targets, such as neurotransmitter systems, ion channels and nitric oxide synthesis. It is an endogenous agonist at **imidazoline receptor** and a **NO synthase** inhibitor.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g

Anemarsaponin B

Cat. No.: HY-N0811

Anemarsaponin B is a steroidal saponin isolated from the rhizomes of A. asphodeloides (Liliaceae). Anemarsaponin B decreases the protein and mRNA levels of **iNOS** and **COX-2**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

AR-C102222 hydrochloride

Cat. No.: HY-12122A

AR-C102222 hydrochloride is a potent, competitive, orally active and highly selective **inducible nitric oxide synthase (iNOS)** inhibitor, with an IC_{50} of 37 nM. AR-C102222 hydrochloride has antinociception and anti-inflammatory activities.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Asperuloside

Cat. No.: HY-N1382

Asperuloside is an iridoid isolated from Hedyotis diffusa, with anti-inflammatory activity. Asperuloside inhibits inducible nitric oxide synthase (**iNOS**), suppresses NF-κB and MAPK signaling pathways.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Asymmetric dimethylarginine

Cat. No.: HY-113216

Asymmetric dimethylarginine is an endogenous inhibitor of **nitric oxide synthase (NOS)**, and functions as a marker of endothelial dysfunction in a number of pathological states.



Purity: >98.0%
Clinical Data:
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

AVE-3085

Cat. No.: HY-19504

AVE-3085 is a potent endothelial **nitric oxide synthase** enhancer, used for cardiovascular disease treatment.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Bendazol

Cat. No.: HY-B2141

Bendazol is a hypotensive drug which can also enhance **NO synthase** activity in renal glomeruli and collecting tubules.



Purity: 99.45%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g

Chondroitin sulfate

(Chondroitin polysulfate)

Cat. No.: HY-B2162

Chondroitin sulfate, one of five classes of glycosaminoglycans, has been widely used in the treatment of osteoarthritis. Chondroitin sulfate reduces inflammation mediators and the apoptotic process and is able to reduce protein production of inflammatory cytokines, **iNOS** and **MMPs**.



Purity: >95.0%
Clinical Data: Launched
Size: 250 mg, 1 g

Ciwujianoside C3

Cat. No.: HY-N4134

Ciwujianoside C3, an orally active and brain penetrated compound, is isolated the leaves of Acanthopanax henryi Harms. Ciwujianoside C3 has anti-inflammatory effect and can reinforces object recognition memory.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Crocin II

Cat. No.: HY-N0698

Crocin II is isolated from the fruit of Gardenia jasminoides with antioxidant, anticancer, and antidepressant activity. Crocin II inhibits NO production with an IC_{50} value of 31.1 μM. Crocin II suppresses the expressions of protein and m-RNA of **iNOS** and **COX-2**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Curvularin

((S)-Curvularin)

Cat. No.: HY-N6770

Curvularin, a fungal metabolite and a potent mycotoxin naturally isolated from Curvularia lunata, inhibits cytokine-induced **nitric oxide synthase (iNOS)**, with an IC_{50} of 9.5 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dehydroevodiamine

Cat. No.: HY-N2106

Dehydroevodiamine is a major bioactive quinazoline alkaloid isolated from Evodiae Fructus, has an antiarrhythmic effect in guinea-pig ventricular myocytes.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Epibetulinic acid

Cat. No.: HY-N0223

Epibetulinic acid, isolated from the root bark of Maytenus cuzcoina and the leaves of Maytenus chiapensis, exhibits potent inhibitory effects on **NO** and prostaglandin E2 (**PGE2**) production in mouse macrophages (RAW 264.7) stimulated with bacterial endotoxin with IC_{50}s of 0.7 and 0.6...



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ermanin

Cat. No.: HY-N3848

Ermanin is a flavonoid isolated from Tanacetum microphyllum. Ermanin potently inhibits **iNOS**, **COX-2** activities, and inhibits platelet aggregation. Ermanin has anti-inflammatory, anti-tuberculous and anti-viral/bacterial properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ethyl Caffeate

Cat. No.: HY-N6966

Ethyl Caffeate is a natural phenolic compound isolated from Bidens pilosa.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Ginsenoside C-K

(Ginsenoside compound K; Ginsenoside K)

Cat. No.: HY-N0904

Ginsenoside C-K, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects by reducing **iNOS** and **COX-2**. Ginsenoside C-K exhibits an inhibition against the activity of **CYP2C9** and **CYP2A6** in human liver microsomes with IC_{50}s of 32.0±3.6 μM and 63.6±4.2 μM, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside Rb3

(Gypenoside IV)

Cat. No.: HY-N0041

Ginsenoside Rb3 is extracted from steamed Panax notoginseng. Ginsenoside Rb3 exhibits inhibitory effect on TNFα-induced **NF-κB** transcriptional activity with an IC_{50} of 8.2 μM in 293T cell lines. Ginsenoside Rb3 also inhibits the induction of **COX-2** and **iNOS** mRNA.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

GW274150

Cat. No.: HY-12119

GW274150 is a potent, selective, orally active and NADPH-dependent inhibitor of human **inducible nitric oxide synthase (iNOS)** (IC_{50}=2.19 μM; K_d=40 nM) and rat **iNOS** (ED_{50}=1.15 μM).



Purity: 98.15%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GW274150 phosphate

Cat. No.: HY-12119A

GW274150 phosphate is a potent, selective, orally active and NADPH-dependent inhibitor of human **inducible nitric oxide synthase (iNOS)** (IC_{50}=2.19 μM; K_d=40 nM) and rat **iNOS** (ED_{50}=1.15 μM).



Purity: 98.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Harpagoside

Cat. No.: HY-N0396

Harpagoside is isolated from Harpagophytum procumbens (Hp). Harpagoside has inhibitory effects on **COX-1** and **COX-2** activity and inhibits NO production.



Purity: 98.35%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Irisflorentin

Cat. No.: HY-N0268

Irisflorentin, a naturally occurring isoflavone, is an abundant active constituent in Rhizoma Belamcandae. Irisflorentin markedly reduces the transcriptional and translational levels of inducible nitric oxide synthase (iNOS) as well as the production of NO. Anti-inflammatory activity.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Isoquercetin

(Quercetin 3-glucoside)

Cat. No.: HY-N1445

Isoquercetin (Quercetin 3-glucoside) is a naturally occurring polyphenol that has antioxidant, anti-proliferative, and anti-inflammatory properties.



Purity: 99.87%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Isosorbide dinitrate

(ISDN)

Cat. No.: HY-B1409

Isosorbide dinitrate (ISDN) is an NO donor that prevents LV remodeling and degradation of cardiac function following myocardial infarction (MI).



Purity: 99.59%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

Kuwanon A

Cat. No.: HY-N2300

Kuwanon A is a flavone derivative isolated from the root barks of the mulberry tree (Morus alba L.); inhibits nitric oxide production with an IC_{50} of 10.5 μM.



Purity: 96.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg

L-Arginine

((S)-(+)-Arginine)

Cat. No.: HY-N0455

L-Arginine is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis. Target: Others L-Arginine is an α-amino acid. It was first isolated in 1886. The L-form is one of the 20 most common natural amino acids.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

L-Arginine hydrochloride

((S)-(+)-Arginine hydrochloride)

Cat. No.: HY-N0455A

L-Arginine hydrochloride ((S)-(+)-Arginine hydrochloride) is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis.



Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

L-Canavanine sulfate

Cat. No.: HY-B1581A

L-Canavanine sulfate is a selective inhibitor of inducible **NO synthase**.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

L-NAME hydrochloride

(NG-Nitroarginine methyl ester hydrochloride)

Cat. No.: HY-18729A

L-NAME hydrochloride inhibits **NOS** with an IC_{50} of 70 μM. L-NAME is a precursor to **NOS** inhibitor L-NOARG which has an IC_{50} value of 1.4 μM.



Purity: 99.07%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 100 mg, 500 mg

L-NIL

Cat. No.: HY-12116

L-NIL is a potent and selective inhibitor of inducible **NO synthase** with IC_{50}s of 3.3 and 92 μM for mouse inducible NO synthase and rat brain constitutive NO synthase, respectively.



Purity: 99.26%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

L-NIO dihydrochloride

Cat. No.: HY-100986

L-NIO dihydrochloride is a potent, non-selective and NADPH-dependent **nitric oxide synthase (NOS)** inhibitor, with K_is of 1.7, 3.9, 3.9 μM for neuronal (nNOS), endothelial (eNOS), and inducible (iNOS), respectively. L-NIO dihydrochloride induces a consistentfocal ischemic infarctin rats.



Purity: >95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

L-NMMA acetate

(Tilarginine acetate; Methylarginine acetate)

Cat. No.: HY-18732A

L-NMMA acetate is a **nitric oxide synthase** inhibitor of all NOS isoforms including NOS1, NOS2, and NOS3. The K_i values for nNOS (rat), eNOS (human), and iNOS (mouse) are approximately 0.18, 0.4, and 6 μM, respectively.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Luteolin 5-O-glucoside

Cat. No.: HY-N2008

Luteolin 5-O-glucoside, a major flavonoidfrom Cirsium maackii, possesses anti-inflammatory activity. Luteolin 5-O-glucoside inhibits LPS-induced **NO** production and t-BHP-induced **ROS** generation. Luteolin 5-O-glucoside suppresses the expression of iNOS and COX-2 in macrophages.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Madecassic acid

Cat. No.: HY-N0569

Madecassic acid is isolated from Centella asiatica (Umbelliferae). Madecassic acid has anti-inflammatory properties caused by **iNOS**, **COX-2**, **TNF-alpha**, **IL-1beta**, and **IL-6** inhibition via the downregulation of **NF-κB** activation in RAW 264.7 macrophage cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Methylene Blue

(Basic Blue 9; Methylthioninium chloride; CI-52015)

Cat. No.: HY-14536

Methylene blue (Basic Blue 9) is a **guanylyl cyclase (sGC)**, **monoamine oxidase A (MAO-A)** and **NO synthase (NOS)** inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures.



Purity: >98.0%
Clinical Data: Launched
Size: 100 mg, 500 mg

Methylene blue trihydrate

(C.I. Basic Blue 9 trihydrate)

Cat. No.: HY-B1359

Methylene blue trihydrate (C.I. Basic Blue 9 trihydrate) is a **guanylyl cyclase (sGC)**, **monoamine oxidase A (MAO-A)** and **NO synthase (NOS)** inhibitor. Methylene blue trihydrate is a vasopressor and is often used as a dye in several medical procedures.



Purity: >97.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Mifepristone

(RU486; RU 38486)

Cat. No.: HY-13683

Mifepristone is a **progesterone receptor** (**PR**) and **glucocorticoid receptor** (**GR**) antagonist with IC_{50}s of 0.2 nM and 2.6 nM in in vitro assay.



Purity: 98.67%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Neocryptotanshinone

Cat. No.: HY-119720

Neocryptotanshinone, a fatty diterpenoids from Salvia Miltiorrhiza, inhibits lipopolysaccharide-induced inflammation by suppression of NF-κB and iNOS signaling pathways.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NOC 18

Cat. No.: HY-136278

NOC 18 is a nitric oxide donor and activates an inward current in cultured rat cerebellar granules cells. NOC 18 increases cGMP production in cultured vascular smooth muscle cells. NOC 18 reduces contractility of cardiac muscle preparations in vitro.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nω-Propyl-L-arginine

(N-omega-Propyl-L-arginine)

Cat. No.: HY-102062

Nω-Propyl-L-arginine (N-omega-Propyl-L-arginine) is a potent, competitive, and highly selective inhibitor of neuronal nitric oxide synthase **(nNOS)**, with a K_i of 57 nM. Nω-Propyl-L-arginine displays a 149-fold selectivity for nNOS over endothelial NOS (eNOS).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Nω-Propyl-L-arginine hydrochloride

(N-omega-Propyl-L-arginine hydrochloride)

Cat. No.: HY-102062A

Nω-Propyl-L-arginine (N-omega-Propyl-L-arginine) hydrochloride is a potent, competitive, and highly selective inhibitor of neuronal nitric oxide synthase **(nNOS)**, with a K_i of 57 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Pectolinarin

Cat. No.: HY-N0314

Pectolinarin, isolated from Cirsium chanroenicum, possesses anti-inflammatory activity. Pectolinarin inhibits secretion of **IL-6** and **IL-8**, as well as the production of **PGE2** and **NO**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Piceatannol 3'-O-glucoside

(Quzhaqigan)

Cat. No.: HY-N2237

Piceatannol 3'-O-glucoside, an active component of Rhubarb, activates endothelial **nitric oxide** (**NO**) **synthase** through inhibition of arginase activity with IC_{50}s of 11.22 μM and 11.06 μM against **arginase I** and **arginase II**, respectively.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 1 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Prim-O-glucosylcimifugin

Cat. No.: HY-N0635

Prim-O-glucosylcimifugin exerts anti-inflammatory effects through the inhibition of **iNOS** and **COX-2** expression by through regulating JAK2/STAT3 signaling.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

S-MTC

Cat. No.: HY-U00432

S-MTC is a selective type I nitric oxide synthase (**NOS**) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

S-Nitroso-N-acetyl-DL-penicillamine

(SNAP)

Cat. No.: HY-121526

S-Nitroso-N-acetyl-DL-penicillamine (SNAP) is a nitric oxide donor and acts as a stable inhibitor of platelet aggregation.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

Syzalterin

Cat. No.: HY-N1187

Syzalterin is an inhibitor of **NO** production with an $\mathbf{IC_{50}}$ of 1.87 μg/mL.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Tat-NR2B9c

(Tat-NR2Bct; NA-1)

Cat. No.: HY-P0117

Tat-NR2B9c (Tat-NR2Bct; NA-1) is a **postsynaptic density-95 (PSD-95)** inhibitor, with $\mathbf{EC_{50}}$ values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively.

YGRKKRRQRRRKLSSIESDV

Purity: 98.22%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Tat-NR2B9c TFA

(Tat-NR2Bct TFA; NA-1 TFA)

Cat. No.: HY-P0117A

Tat-NR2B9c TFA (Tat-NR2Bct TFA) is a postsynaptic density-95 (PSD-95) inhibitor, with $\mathbf{EC_{50}}$ values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively.

YGRKKRRQRRRKLSSIESDV (TFA salt)

Purity: 98.99%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Tat-NR2Baa

Cat. No.: HY-P2307

Tat-NR2BAA is the **control peptide** of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95.

YGRKKRRQRRRKLSSIEADA

Purity: 96.26%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Tat-NR2Baa TFA

Cat. No.: HY-P2307A

Tat-NR2BAA TFA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA TFA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95.

YGRKKRRQRRRKLSSIEADA (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tetrahydrobiopterin

(Sapropterin)

Cat. No.: HY-107383

Tetrahydrobiopterin is a **cofactor** of the **aromatic amino acid hydroxylases enzymes** and also acts as an essential **cofactor** for all **nitric oxide synthase** (NOS) isoforms.

Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

TP508

Cat. No.: HY-P0316

TP508 is a 23-amino acid nonproteolytic **thrombin** peptide that represents a portion of the receptor-binding domain of thrombin molecule. TP508 activates endothelial **NO synthase (eNOS)** and stimulates production of NO in human endothelial cells.

AGYKPDEGKRGDACEGDSGGPFV

Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

TP508 TFA

Cat. No.: HY-P0316A

TP508 TFA is a 23-amino acid nonproteolytic **thrombin** peptide that represents a portion of the receptor-binding domain of thrombin molecule. TP508 TFA activates endothelial **NO synthase (eNOS)** and stimulates production of NO in human endothelial cells.

AGYKPDEGKRGDACEGDSGGPFV (TFA salt)

Purity: 98.87%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

α-Humulene

(Humulene; α-Caryophyllene)

Cat. No.: HY-N6968

α-Humulene is a main constituent of Tanacetum vulgare L. (Asteraceae) essential oil with anti-inflammation (IC_{50}=15±2 μg/mL). α-Humulene inhibits **COX-2** and **iNOS** expression.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg